European journal of internal medicine
-
Eur. J. Intern. Med. · Feb 2022
Off-label use of biologics for the treatment of refractory and/or relapsing granulomatosis with polyangiitis.
To describe the efficacy and safety of off-label use of biologics for refractory and/or relapsing granulomatosis with polyangiitis (GPA). ⋯ This real-life study suggests that off-label use of anti-TNF-α and abatacept shows efficacy in less than 50% of refractory and/or relapsing GPA.